Refractory Acute Myeloid Leukemia Clinical Trials in New York, New York

6 studies are recruiting for refractory acute myeloid leukemia in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

   This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory) who have undergone allogenic…

   Stage

   Phase 1

   Ages

   Up to 21

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   11 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07012044 on ClinicalTrials.gov

2. Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

   This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that did not go into remission after …

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   Memorial Sloan- Kettering Cancer Center, New York, New York

   Locations

   10 in total

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT06177067 on ClinicalTrials.gov

3. A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

   The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.

   Stage

   Phase 1

   Ages

   1 and older

   Site

   Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06017258 on ClinicalTrials.gov

4. A Study of CRD3874-SI in People With Leukemia

   The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid leukemia (AML).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07661095 on ClinicalTrials.gov

5. Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

   This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may stop the growth of cancer cells by blocking some of the enzymes…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   22 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06484062 on ClinicalTrials.gov

6. A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

   Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1, Part 1 Dose Escalation - Monotherapy will evaluate the sa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   13 in total

   Run by

   BlossomHill Therapeutics

   See if you can join NCT06501196 on ClinicalTrials.gov